⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
NAD+ Precursors (NR / NMN)
Current understanding
Raises NAD+ levels reliably; clinical outcome benefits remain unproven.
Evidence log
- 2026-03-31 — Reprogramming the mitochondrial-circadian energy code with incretins.: [mechanism-plausible] Review, no new primary data: biology suggests NAD+ support could complement incretin-linked mitochondrial and circadian regulation, but the proposed combination does not establish NR/NMN-specific efficacy, and no outcome study presented confirms added healthspan or lifespan benefit. [mechanism-plausible] (novelty: 3)
- 2026-11-01 — A Cilia-Centered Nicotinamide Adenine Dinucleotide (NAD) Signaling Network Regulates Hypothalamic Lysosomal Homeostasis and Metabolic Aging.: [animal-model] Preclinical study links hypothalamic NAD+ depletion to impaired primary cilia and CHMP4B-mediated lysosomal repair during metabolic aging, with calorie restriction reversing the dysfunction; this is not evidence that NR/NMN supplementation reproduces the effect or benefits humans. [animal-model] (novelty: 3)
- 2026-10-02 — Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults: Confirmatory RCT launched to test whether 3 months of oral nicotinamide riboside lowers systolic BP and arterial stiffness in middle-aged/older adults with SBP 120–139 mmHg, following a pilot that reported ~8 mmHg SBP reduction vs placebo — early-trial step on a cardiovascular surrogate, outcome data pending. [human-rct] (novelty: 3)
- 2026-10-06 — Unlicensed Bronx practitioner charged with murder in anti-aging NAD injection death: CBS News report (Nov 2025): unlicensed Bronx practitioner charged with murder after a client died following an anti-aging NAD injection — safety/regulatory signal from the unregulated longevity-clinic injection trend, not efficacy data. [anecdotal-biohack] (novelty: 3)
- 2026-07-28 — Enhancing the anti-ageing capacity of hUC-MSCs via NMN co-treatment in D-galactose-induced ageing mice and cellular senescence models.: D-galactose aging mouse + cellular senescence study: co-administration of hUC-MSCs with NMN outperformed either monotherapy, with NMN protecting transplanted MSCs from senescence via Nrf2/HO-1 activation — combinatorial preclinical signal pairing NAD precursor with cell therapy, no human data. [animal-model] (novelty: 3)
- 2025-11-22 — Nicotinamide riboside supplementation restores microglial health and improves cognition in aged male mice.: 8-week nicotinamide riboside (400 mg/kg) in aged male mice improved cognition and shifted microglial transcriptome and metabolism from ADEM/DAM-like toward a younger homeostatic phenotype — extends NR benefits into brain microglial aging, animal only. [animal-model] (novelty: 3)
- 2026-07-21 — β-Nicotinamide mononucleotide reduces aflatoxin B1 induced liver injury via the gut microbiota-bile acid-farnesoid X receptor (FXR/NR1H4) axis.: Mouse study of oral NMN in aflatoxin B1-induced liver injury showed hepatoprotection via gut microbiota reshaping, raised BSH activity, lowered conjugated bile acids, and intestinal FXR/FGF15 activation suppressing hepatic Cyp7a1 — causally supported by antibiotic, FMT, and intestine-specific FXR knockout experiments; extends NMN mechanism beyond NAD+ repletion into a gut–bile acid axis, no human outcome. [animal-model] (novelty: 3)
- 2026-07-16 — Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol.: Phase 2a multicenter RCT protocol (MIB-626 pharmaceutical-grade β-NMN, 1000 mg BID × 24 weeks) in adults with diabetic kidney disease, with urinary ACR plus kidney and biological-age markers as endpoints — registers a clinical development step for NAD precursors in an outcome-relevant disease population, but no efficacy data yet. [human-rct] (novelty: 3)
- 2026-05-25 — A sustained NADsupplementation-biosynthesis nanoplatform for metabolic restoration in aged bone regeneration.: Preclinical nanoplatform study (N/S@M@P) combining sustained NAD supplementation with biosynthesis support restored NAD/NADH and ATP in senescent BMSCs, reduced senescent fraction, and improved bone regeneration in aged mouse bone defects — delivery-innovation on the NAD-restoration axis, not a first-in-class mechanism and not a human outcome. [animal-model] (novelty: 3)
- 2026-08-29 — NADprecursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria.: Chronic nicotinamide riboside in mitochondrial-progeria (mutator) mice prevented cardiomyopathy in postmitotic heart tissue but induced reductive stress in bone marrow that disrupted erythroid maturation and worsened anemia — tissue-specific dual-effect caveat for NAD-boosting strategies. [animal-model] (novelty: 3)
- 2026-09-16 — Endothelial C/EBPβ/AEP pathway drives vascular deterioration and systemic aging.: Mouse study framing NMN as a comparator: endothelial C/EBPβ/AEP–driven NAMPT cleavage depletes systemic NAD+, and NMN partially mitigated vascular/systemic aging but was outperformed by the upstream AEP inhibitor CP#11A — supports the NAD-depletion premise while suggesting substrate loading may be a downstream fix relative to blocking NAMPT proteolysis. [animal-model] (novelty: 4)
- 2026-09-20 — NAD-sirtuin-mitochondrial quality control in lens epithelial cells: a candidate modulatory network in crystalline lens aging.: Narrative review proposes the NAD–sirtuin–mitochondrial quality control network in lens epithelial cells as a candidate modulator of crystalline lens aging (cataract/presbyopia), while noting age-dependent NAD change in normal human LECs and any causal epithelium-to-tissue pathway remain unproven — conceptual framing, no new outcome data. [mechanism-plausible] (novelty: 3)
- 2026-09-20 — Preliminary findings on the enhancement of skeletal muscle structure and function in aged male mice by P7C3 activation of nicotinamide phosphoribosyl transferase (NAMPT).: Adjacent NAD-salvage evidence: P7C3-driven NAMPT activation (rather than NR/NMN substrate loading) improved muscle contractility, myofiber size, and grip strength in aged male mice — supports the NAD-salvage rationale via a different pharmacologic entry point, not an NR/NMN outcome. [animal-model] (novelty: 3)
- 2026-09-18 — Imeglimin provides dual hepatic and skeletal muscle protection in experimental MASH-associated sarcopenia.: cross-connection with imeglimin: Imeglimin’s muscle/liver protection was accompanied by restored NAD+/NAMPT, overlapping mechanistically with NAD+ precursor rationale (animal-model). (novelty: 3)
- 2026-09-11 — Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies.: Same review nominates NAD+ precursors as one arm of a precision-matched mitochondrial-repair toolkit for OP/OA/RA, linked to sirtuin-driven mitochondrial biogenesis and quality control — conceptual framing, no new bone/joint outcome data. [mechanism-plausible] (novelty: 3)
- 2026-09-10 — NAD+ Metabolic Reprogramming Drives CD8+ T Cells Senescence and Exacerbates Ulcerative Colitis: Preclinical ulcerative colitis study: NAD+ metabolic reprogramming in CD8+ T cells drove their senescence and worsened colitis severity — a mechanistic link between NAD+ biology and immune-cell aging in IBD, but no NR/NMN intervention outcome data. [animal-model] (novelty: 3)
- 2026-09-01 — NADMetabolic Reprogramming Drives CD8T Cells Senescence and Exacerbates Ulcerative Colitis.: Preclinical UC study: NAD metabolic dysregulation in CD8 T cells drove mitochondrial dysfunction and cGAS–STING-dependent T-cell senescence exacerbating colitis, implicating the NAD salvage axis in immune-cell senescence — mechanistic support for NAD repletion in IBD, but no NR/NMN outcome data provided. [animal-model] (novelty: 3)
- 2026-03-02 — Iridoids from the edible flowers of Rhododendron pachypodum: structural elucidation and healthspan related bioactivities in Caenorhabditis elegans.: Used as the comparator (not the intervention) in a C. elegans screen of Rhododendron pachypodum iridoids, where two novel iridoids exceeded NMN on lifespan and healthspan endpoints — a worm-level benchmark, not a human or mammalian NMN outcome. [animal-model] (novelty: 3)
- 2026-06-26 — Meta-analysis of DNA methylation aging signatures in 17 human tissues.: Multi-tissue DNA methylation meta-analysis (>15,000 profiles, 17 human tissues) identifies an NAD-metabolism-linked gene cluster as a modifiable component of conserved epigenetic aging signatures — associative/methylation-level signal, not an NR/NMN outcome trial. [human-observational] (novelty: 3) [human-observational] (novelty: 3)
- 2026-07-03 — PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.: PROMETHEUS feasibility protocol (n=20, 8 weeks) assigns NMN as a gerotype-tailored augment based on baseline phenotype; personalisation design, no outcome data. [expert-opinion] (novelty: 3)
- 2026-07-01 — The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics.: Ocular aging review positions NAD+ metabolism (and NAD+ precursor repletion) as a tissue-resilience node for RPE and neurovascular unit maintenance in age-related eye disease — conceptual framing, no new ocular outcome data. [mechanism-plausible] (novelty: 3)
- 2026-08-10 — Fibrillarin Resists Cellular Senescence Via SIRT1-Dependent Nicotinamide Metabolism and Its Inhibition Sensitizes Senolytic Therapy in Esophageal Squamous Cell Carcinoma.: cross-connection with senolytics: Fibrillarin’s anti-senescence action runs through SIRT1-dependent nicotinamide (NAD+ salvage) metabolism, linking senolytic sensitization to the same NAD+/sirtuin axis targeted by NR/NMN supplementation. (novelty: 3)
- 2026-07-09 — Cell-Type-Specific Calibration of Mitochondrial Ubiquitination in Stem Cell Fate Decisions.: 2025 mechanistic review frames NAD+ as a hematopoietic stem cell mitophagy checkpoint feeding into PINK1–Parkin ubiquitination, positioning NAD+ precursors within a cell-type-specific mitochondrial quality-control framework (review, no new outcome data). [mechanism-plausible] (novelty: 3)
- 2026-08-01 — The Divergent Effects of Nicotinamide Riboside and High-Intensity Exercise Training on Skeletal Muscle Epigenetic Aging.: Five-month NR supplementation reduced skeletal-muscle epigenetic age acceleration on several clocks in humans, with EAA shifts correlating with mitochondrial content — contrasting with 4–6 weeks of HIIT which increased pace of aging on some clocks (early human trial data, surrogate endpoint). [human-rct] (novelty: 3)
Open questions
Related
Contributing findings
A Cilia-Centered Nicotinamide Adenine Dinucleotide (NAD) Signaling Network Regulates Hypothalamic Lysosomal Homeostasis and Metabolic Aging.
01-nov-2026
novelty 3
per-area 3
strengthens
Rapid Wound Healing Observed Following Oral LathMized NAD+ Supplementation: A Case Study.
19-oct-2026
novelty 2
per-area 2
strengthens
Mitochondria-targeted drug delivery systems for aging-related diseases: Mechanisms, strategies, and advances.
16-oct-2026
novelty 2
per-area 2
mentions
Association of Frailty Status with Semi-Targeted Metabolomics and Untargeted Proteomics in Older Adults Referred for Physical Therapy in a Geriatric Clinic.
12-oct-2026
novelty 2
per-area 2
mentions
THE AGING PURINOME: A PURINERGIC FRAMEWORK LINKING THE HALLMARKS OF AGING TO INFLAMMAGING.
10-oct-2026
novelty 3
per-area 2
strengthens
Unlicensed Bronx practitioner charged with murder in anti-aging NAD injection death
06-oct-2026
novelty 3
per-area 3
strengthens
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
02-oct-2026
novelty 3
per-area 3
strengthens
Supplements for Longevity Are Everywhere, but Do They Actually Work? Experts Break Down the Science
02-oct-2026
novelty 2
per-area 1
mentions
Sirtuin signaling as therapeutic targets of immunosenescence.
25-sep-2026
novelty 2
per-area 2
strengthens
Metabolism of Nicotinamide Adenine Dinucleotide+ in Atherosclerosis: Mechanisms and Nutritional Modulation.
23-sep-2026
novelty 2
per-area 2
strengthens
NAD-sirtuin-mitochondrial quality control in lens epithelial cells: a candidate modulatory network in crystalline lens aging.
20-sep-2026
novelty 3
per-area 3
strengthens
Preliminary findings on the enhancement of skeletal muscle structure and function in aged male mice by P7C3 activation of nicotinamide phosphoribosyl transferase (NAMPT).
20-sep-2026
novelty 3
per-area 3
strengthens
Endocrine and Molecular Mechanisms of Oocyte Aging: From Gonadotropin Signaling to Metabolic and Microenvironmental Dysfunction.
19-sep-2026
novelty 2
per-area 2
mentions
Therapeutic Targeting of Inflammaging and Emerging Strategies for Managing Age-Related Multimorbidity: A Narrative Review.
19-sep-2026
novelty 2
per-area 2
strengthens
Endothelial C/EBPβ/AEP pathway drives vascular deterioration and systemic aging.
16-sep-2026
novelty 4
per-area 4
strengthens
The dimorphic brain in ischemic stroke: How sex and age shape molecular pathophysiology and therapeutic responsiveness.
16-sep-2026
novelty 2
per-area 2
strengthens
Aging as Loss of Biological Self-Correction: A Geroscience Framework for Longevity, Inflammaging, and Restored Resilience.
16-sep-2026
novelty 3
per-area 2
mentions
Mitochondrial homeostasis in musculoskeletal diseases: From pathogenic mechanisms to precision therapies.
11-sep-2026
novelty 3
per-area 3
strengthens
Bazi Bushen attenuates musculoskeletal degeneration in Ercc1mice.
10-sep-2026
novelty 3
per-area 2
mentions
Mitochondrial homeodynamics in ageing: mechanisms, resilience, and interventions.
10-sep-2026
novelty 3
per-area 2
mentions
NAD+ Metabolic Reprogramming Drives CD8+ T Cells Senescence and Exacerbates Ulcerative Colitis
10-sep-2026
novelty 3
per-area 3
strengthens
Subcellular sirtuin signaling networks: pivotal regulators of cardiovascular homeostasis and remodeling.
10-sep-2026
novelty 2
per-area 2
mentions
NADMetabolic Reprogramming Drives CD8T Cells Senescence and Exacerbates Ulcerative Colitis.
01-sep-2026
novelty 3
per-area 3
strengthens
NADprecursor treatment prevents cardiomyopathy but disrupts erythroid maturation in mitochondrial progeria.
29-aug-2026
novelty 3
per-area 3
strengthens
The Reductive Stress Nexus: Integrated Pathways of Metabolic Dysregulation, Senescence and Blood-Brain Barrier Failure in Neurodegenerative Disease and Brain Aging.
26-aug-2026
novelty 3
per-area 2
mentions
A Staged Translational Framework for Evaluating Oral Glutamatergic and Senescence-Modulating Strategies in Treatment-Resistant Depression.
24-aug-2026
novelty 2
per-area 2
mentions
Nicotinamide Mononucleotide (NMN) Prevents Age-Associated Transcriptional Drift in a Tissue-Dependent Manner: Mechanistic Leads From Ras-Related Protein Rab-11A-Mediated Trafficking and Carnitine Palmitoyltransferase 2-Linked Fatty Acid Oxidation.
21-aug-2026
novelty 2
per-area 2
strengthens
A minimal three-arm oral regimen for healthspan: mechanistic alignment with transcriptomic signals from a large parental-lifespan GWAS.
19-aug-2026
novelty 2
per-area 2
strengthens
High-fructose diet-induced gut dysbiosis as a mechanistic driver of chronic inflammation and accelerated biological aging: a comprehensive review.
13-aug-2026
novelty 2
per-area 2
mentions
Tumor immunosenescence drives breast cancer progression and therapeutic resistance: mechanisms and emerging interventions.
07-aug-2026
novelty 2
per-area 2
mentions
The Divergent Effects of Nicotinamide Riboside and High-Intensity Exercise Training on Skeletal Muscle Epigenetic Aging.
01-aug-2026
novelty 3
per-area 3
strengthens
Enhancing the anti-ageing capacity of hUC-MSCs via NMN co-treatment in D-galactose-induced ageing mice and cellular senescence models.
28-jul-2026
novelty 3
per-area 3
strengthens
β-Nicotinamide mononucleotide reduces aflatoxin B1 induced liver injury via the gut microbiota-bile acid-farnesoid X receptor (FXR/NR1H4) axis.
21-jul-2026
novelty 3
per-area 3
strengthens
Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans
21-jul-2026
novelty 2
per-area 2
strengthens
Nicotinamide Adenine Dinucleotide Augmentation in Diabetic Kidney Disease: Randomized Trial Study Protocol.
16-jul-2026
novelty 3
per-area 3
strengthens
Mechanistic intersections of empagliflozin and nebivolol in aging-associated redox and inflammatory pathways.
16-jul-2026
novelty 2
per-area 1
mentions
Mitochondrial-ER stress crosstalk in osteoarthritis: From ageing-associated chondrocyte dysfunction to emerging therapeutics.
10-jul-2026
novelty 2
per-area 2
mentions
Cell-Type-Specific Calibration of Mitochondrial Ubiquitination in Stem Cell Fate Decisions.
09-jul-2026
novelty 3
per-area 3
strengthens
Sirtuins in Alzheimer's disease: Global research trends and bibliometric insights.
06-jul-2026
novelty 2
per-area 2
mentions
Aging-driven metabolic abnormalities remodel intercellular communication through the gut-liver-heart axis and may promote coronary artery disease: the key role of bile acid metabolism.
06-jul-2026
novelty 2
per-area 2
mentions
PROMETHEUS clinical trial protocol: tailoring healthy ageing with lifestyle and nutraceuticals.
03-jul-2026
novelty 3
per-area 3
strengthens
The Molecular Basis of Ocular Aging: Mechanisms, Pathologies, and Emerging Therapeutics.
01-jul-2026
novelty 3
per-area 3
strengthens
Meta-analysis of DNA methylation aging signatures in 17 human tissues.
26-jun-2026
novelty 3
per-area 3
strengthens
Food Supplement for Longevity
22-jun-2026
novelty 2
per-area 2
mentions
A sustained NADsupplementation-biosynthesis nanoplatform for metabolic restoration in aged bone regeneration.
25-may-2026
novelty 3
per-area 3
strengthens
Nicotinamide mononucleotide (NMN) improves the ovarian microenvironment associated with oocyte quality by increasing estrogen signaling, reprogramming ovarian metabolism, reducing oxidative stress, and inhibiting apoptosis in the spotted scat (Scatophagus argus).
05-may-2026
novelty 2
per-area 2
strengthens
Reprogramming the mitochondrial-circadian energy code with incretins.
31-mar-2026
novelty 3
per-area 3
strengthens
Iridoids from the edible flowers of Rhododendron pachypodum: structural elucidation and healthspan related bioactivities in Caenorhabditis elegans.
02-mar-2026
novelty 3
per-area 3
strengthens
Restoring NAD⁺-Sirtuins Signaling: A Novel Approach to Combat Male Reproductive Aging.
06-feb-2026
novelty 2
per-area 3
strengthens
Nicotinamide riboside supplementation restores microglial health and improves cognition in aged male mice.
22-nov-2025
novelty 3
per-area 3
strengthens